

bs-1728R**[Primary Antibody]****CX3CR1 Rabbit pAb**

Bioss
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

DATASHEET**Host:** Rabbit**Isotype:** IgG**Clonality:** Polyclonal**GeneID:** 1524**SWISS:** P49238**Target:** CX3CR1**Immunogen:** KLH conjugated synthetic peptide derived from human CX3CR1: 151-250/355. < Extracellular >**Purification:** affinity purified by Protein A**Concentration:** 1mg/ml**Storage:** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.


Background: Fractalkine is a transmembrane protein and chemokine involved in the adhesion and migration of leukocytes. The protein encoded by this gene is a receptor for fractalkine. The encoded protein also is a coreceptor for HIV-1, and some variations in this gene lead to increased susceptibility to HIV-1 infection and rapid progression to AIDS. Four transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jan 2010]

Applications: WB (1:500-2000)**IHC-P** (1:100-500)**IHC-F** (1:100-500)**IF** (1:100-500)**Flow-Cyt** (1ug/Test)


Reactivity: Mouse, Rat
(predicted: Human, Rabbit, Cow, Dog)

Predicted MW.: 39 kDa


Subcellular Location: Cell membrane

VALIDATION IMAGES


Sample: Heart(Mouse) Lysate at 40 ug Heart(Rat) Lysate at 40 ug Primary: Anti-CX3CR1 (bs-1728R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 50/55 kD Observed band size: 53 kD



Sample: Lane 1: Mouse Spinal cord tissue lysates Lane 2: Mouse Cerebrum tissue lysates Lane 3: Rat Spinal cord tissue lysates Lane 4: Rat Cerebrum tissue lysates Primary: Anti-CX3CR1 (bs-1728R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 39 kDa Observed band size: 47 kDa



Paraformaldehyde-fixed, paraffin embedded (rat spinal cord); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (CX3CR1) Polyclonal Antibody, Unconjugated (bs-1728R) at 1:1000 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.



Blank control: Raw264.7. Primary Antibody (green line): Rabbit Anti-CX3CR1 antibody (bs-1728R) Dilution: 1ug/Test; Secondary Antibody: Goat anti-rabbit IgG-FITC Dilution: 0.5ug/Test. Protocol The cells were incubated in 5% BSA to block non-specific protein-protein interactions for 30 min at room temperature

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

.Cells stained with Primary Antibody for 30 min
at room temperature. The secondary antibody
used for 40 min at room temperature.
Acquisition of 20,000 events was performed.

— SELECTED CITATIONS —

- **[IF=11.99]** Sun et al. Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos. (2017) J.Exp.Med. 214:1753-1767 IHC ;Mouse. 28465464
- **[IF=8.2]** Cheng Miao. et al. M1 Macrophage-Derived Extracellular Vesicles Loaded with CX3CR1 siRNA for the Treatment of Pancreatic Cancer. ACS APPL MATER INTER. 2025;XXXX(XXX):XXX-XXX WB ;Human. 40600720
- **[IF=5.9]** Duliurui Huang. et al. Analysis of the heterogeneity and complexity of murine extraorbital lacrimal gland via single-cell RNA sequencing. OCUL SURF. 2024 Jun;; IF ;Mouse. 38945476
- **[IF=5.085]** Venosa Alessandro. et al. Role of CCR2+ Myeloid Cells in Inflammation Responses Driven by Expression of a Surfactant Protein-C Mutant in the Alveolar Epithelium. Front Immunol. 2021 Apr;12:1348 IHC ;Mouse. 33968067
- **[IF=5.215]** Tianrui Zhang. et al. Daphnetin Improves Neuropathic Pain by Inhibiting the Expression of Chemokines and Inflammatory Factors in the Spinal Cord and Interfering with Glial Cell Polarization. PHARMACEUTICALS-BASE. 2023 Feb;16(2):243 WB ;Rat. 10.3390/ph16020243